Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    TCR2 THERAPEUTICS INC. logo
    TCRR

    TCR2 THERAPEUTICS INC.

    MaveScore 20 Low model confidence
    Last Price US$1.48 As of Updating
    Market Cap US$58.1m Company size context
    7D Performance N/A Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2023

    898 days old

    Market price date

    Updating

    Refreshing

    Coverage

    11/16

    5 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 20 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    11/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    17/35 Mixed

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    0/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    1/15 Weak

    Momentum

    Momentum needs recent 3-month or 6-month price-change data.

    0/15 Needs Data

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    2/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
    • Momentum needs recent 3-month or 6-month price-change data.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin, latest price, 3-month price change, 6-month price change.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    TCR2 THERAPEUTICS INC. Overview

    Industry: Biotechnology

    Sector: Healthcare

    TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

    TCR2 THERAPEUTICS INC. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review TCR2 THERAPEUTICS INC. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    TCR2 THERAPEUTICS INC. Competitors

    TCR2 THERAPEUTICS INC. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    TCR2 THERAPEUTICS INC.

    US$1.48

    US$58.1m

    N/A

    N/A